Kyntra Bio (LTS:0IL8) E10: $-42.95 (As of Mar. 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
50 GF Score
Price $7.45
GF Value $5.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio E10?

Kyntra Bio LTS:0IL8 -1.94% 50 E10 is $-42.95 as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kyntra Bio's adjusted earnings per share data for the three months ended in Mar. 2026 was $-3.760. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-42.95 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-09), Kyntra Bio's current stock price is $7.4531. Kyntra Bio's E10 for the quarter that ended in Mar. 2026 was $-42.95. Kyntra Bio's Shiller PE Ratio of today is .


Kyntra Bio  (LTS:0IL8) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kyntra Bio E10 Related Terms


Kyntra Bio E10 Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio E10 Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -53.25 -49.61 -43.28

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.05 -66.01 -46.33 -43.28 -42.95

LTS:0IL8 vs TVGN, PSTV, GRDX: E10 Comparison

For the Biotechnology subindustry, Kyntra Bio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Shiller PE Ratio falls into.


LTS:0IL8
50GF Score
Kyntra Bio Inc LTS:0IL8
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyntra Bio's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3.76/330.2130*330.2130
=-3.760

Current CPI (Mar. 2026) = 330.2130.

Kyntra Bio Quarterly Data

per share eps CPI Adj_EPS
201606 8.750 241.018 11.988
201609 -9.500 241.428 -12.994
201612 -12.250 241.432 -16.755
201703 -12.000 243.801 -16.253
201706 -11.500 244.955 -15.503
201709 -8.000 246.819 -10.703
201712 -6.750 246.524 -9.041
201803 -12.500 249.554 -16.540
201806 -7.000 251.989 -9.173
201809 -12.500 252.439 -16.351
201812 5.750 251.233 7.558
201903 -13.250 254.202 -17.212
201906 31.500 256.143 40.609
201909 -14.250 256.759 -18.327
201912 -28.000 256.974 -35.980
202003 -22.250 258.115 -28.465
202006 -23.750 257.797 -30.421
202009 8.750 260.280 11.101
202012 -16.000 260.474 -20.284
202103 -19.500 264.877 -24.310
202106 -36.250 271.696 -44.057
202109 13.500 274.310 16.251
202112 -36.250 278.802 -42.934
202203 -17.000 287.504 -19.525
202206 -19.500 296.311 -21.731
202209 -24.500 296.808 -27.257
202212 -17.500 296.797 -19.470
202303 -20.250 301.836 -22.154
202306 -22.500 305.109 -24.351
202309 -16.250 307.789 -17.434
202312 -14.250 306.746 -15.340
202403 -8.250 312.332 -8.722
202406 -3.890 314.175 -4.089
202409 -4.250 315.301 -4.451
202412 4.500 315.605 4.708
202503 1.150 319.799 1.187
202506 -1.880 322.561 -1.925
202509 49.610 324.800 50.437
202512 -3.510 324.054 -3.577
202603 -3.760 330.213 -3.760

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-42.95 mean?
Kyntra Bio (LTS:0IL8) has a E10 of $-42.95 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's E10 too high?
Kyntra Bio's current E10 is $-42.95. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's E10 compare to TVGN and PSTV?
Kyntra Bio's E10 of $-42.95 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current E10 is $-42.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current E10 is $-42.95. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current E10 is $-42.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • E10: $-42.95
  • GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score

Get the complete analysis for LTS:0IL8

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$5.70
GF Value